Characteristics, treatments, and causes of death for patients with iTTP
| . | Data for patients with iTTP (n = 83) . |
|---|---|
| Demographic information | |
| Age, y | 58 (41.5-69.0) |
| Sex, female/male | 48/35 |
| Background | |
| Primary iTTP | 68 |
| Autoimmune disease | 12 |
| Pregnancy | 1 |
| Other | 2 |
| Laboratory data | |
| Platelet count, ×109/L | 11 (8-16) |
| ADAMTS13 activity, % | <0.5 (<0.5 to <0.5) |
| ADAMTS13 inhibitors, BU/mL | 3.05 (1.8-5.6) |
| Lactate dehydrogenase, U/L | 930 (658-1328) |
| Hemoglobin, g/dL | 7.8 (6.7-9.0) |
| Serum creatinine, mg/dL | 0.91 (0.7-1.28) |
| Total bilirubin, mg/dL | 2.9 (2.3-4.4) |
| Outcome | |
| Follow-up periods, d | 432 |
| TTP-related death | 11 |
| Non–TTP-related death (causes of death) | 4 (2 sepsis, 1 liver failure, and 1 subcortical hemorrhage) |
| . | Data for patients with iTTP (n = 83) . |
|---|---|
| Demographic information | |
| Age, y | 58 (41.5-69.0) |
| Sex, female/male | 48/35 |
| Background | |
| Primary iTTP | 68 |
| Autoimmune disease | 12 |
| Pregnancy | 1 |
| Other | 2 |
| Laboratory data | |
| Platelet count, ×109/L | 11 (8-16) |
| ADAMTS13 activity, % | <0.5 (<0.5 to <0.5) |
| ADAMTS13 inhibitors, BU/mL | 3.05 (1.8-5.6) |
| Lactate dehydrogenase, U/L | 930 (658-1328) |
| Hemoglobin, g/dL | 7.8 (6.7-9.0) |
| Serum creatinine, mg/dL | 0.91 (0.7-1.28) |
| Total bilirubin, mg/dL | 2.9 (2.3-4.4) |
| Outcome | |
| Follow-up periods, d | 432 |
| TTP-related death | 11 |
| Non–TTP-related death (causes of death) | 4 (2 sepsis, 1 liver failure, and 1 subcortical hemorrhage) |
Demographic information, background, laboratory data, treatment, and outcomes of all patients (n = 83) were collected and summarized. Data are presented as the number of patients or median and first to third interquartile range (median [1IQR-3IQR]).